New hope for controlling debilitating nosebleeds in rare disease

NCT ID NCT03850964

Summary

This study is testing whether a drug called pazopanib can help people with hereditary hemorrhagic telangiectasia (HHT), a genetic disorder that causes frequent, severe nosebleeds and anemia. About 70 participants will take either pazopanib or a placebo pill daily for 24 weeks to see if it reduces nosebleed duration and improves blood counts. The goal is to better control the disease's symptoms and reduce the need for blood transfusions.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Augusta University

    Augusta, Georgia, 30912, United States

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • John Hopkins University

    Baltimore, Maryland, 21287, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • University of California - Los Angeles

    Los Angeles, California, 90095, United States

  • University of Colorado

    Denver, Colorado, 80045, United States

  • University of North Carolina

    Chapel Hill, North Carolina, 27514, United States

  • University of Texas - Southwestern

    Dallas, Texas, 75390, United States

  • University of Utah Medical Center

    Salt Lake City, Utah, 84132, United States

  • Washington University

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.